Crizotinib, commercialized as Xalkori®, is an oral receptor tyrosine kinase inhibitor (TKI) targeting MET, RON, and ALK [24] that was approved by the FDA for the treatment of non-small cell lung cancer in 2011. This evidence concerns the gene MET and non-small cell lung carcinoma.